Multiple Myeloma: Is it time to rethink how we sequence treatments? - Post-Meeting Survey - 13-01-2026

Thank you for attending “Multiple Myeloma: Is it time to rethink how we sequence treatments?”

To improve future events please can you complete the following survey.

This survey has been created by Menarini Stemline and is intended for UK healthcare professionals with an interest in multiple myeloma, and who attended the Experts Knowledge Share meeting.

Please refer to the NEXPOVIO® (selinexor) SmPC for more information.

Adverse event reporting information can be found at the bottom of this page.

Name *

Email Address *

Please select your role from the list below:

The content of the meeting was informative and relevant to my clinical practice. Strongly agreeAgreeDisagreeStrongly disagree

The format of the meeting was engaging and promoted learning.Strongly agreeAgreeDisagreeStrongly disagree

To what extent do you agree that the information presented during Session 1: “Myeloma bench to bedside: considerations at each line of therapy”, resonated with your clinical practice? Strongly agreeAgreeDisagreeStrongly disagree

To what extent do you agree that the information presented during Session 2: “Every move matters: rethinking sequencing strategies in modern myeloma”, resonated with your clinical practice? Strongly agreeAgreeDisagreeStrongly disagree

To what extent do you agree that the information presented during Session 3: “Clinical studies to clinical reality: patient case studies”, resonated with your clinical practice? Strongly agreeAgreeDisagreeStrongly disagree

To what extent do you agree that the meeting has increased my awareness and overall understanding of the applications of NEXPOVIO® (selinexor) in patients with multiple myeloma who meet the licensed indications. Strongly agreeAgreeDisagreeStrongly disagree

The meeting has increased my confidence in prescribing NEXPOVIO® to eligible patients with multiple myeloma who are seen in my clinic. Strongly agreeAgreeDisagreeStrongly disagree

What are the key insights that you gained about NEXPOVIO® and/or relapsed/refractory multiple myeloma from your attendance at the meeting?

What additional resources or topics would you like to see in future meetings and events to enhance your understanding of relapsed refractory multiple myeloma?

Licensed indication

NEXPOVIO^®(selinexor) is indicated:¹

In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA yellow card in the Google Play or Apple App Store. Adverse events should also be reported to Menarini Stemline via e-mail at adverseevents@menarinistemline.com or telephone toll-free on +44 (0)800 047 8675.

MAT-GB-SEL-00754

Multiple Myeloma: Is it time to rethink how we sequence treatments? - Post-Meeting Survey - 13-01-2026

Products

SUPPORT